Introduction
The unsolved challenge for HIV treatment is to eradicate persistent latent reservoirs in infected individuals maintained on combination antiretroviral therapy (ART). 'Shock and kill' approaches have been proposed as cure strategies for HIV [1] . Treatment with drugs that activate HIV out of latency (shock), combined with continued ART to prevent the spread of infection, may allow the host immune system to eliminate latently infected cells (kill) [2] . Numerous drugs have been proposed to provide the 'shock' in a shock and kill strategy towards an HIV cure, including histone deacetylase inhibitors (HDACis), protein kinase C agonists (e.g. ingenol derivatives and bryostatin), bromodomain inhibitors (e.g. JQ1), among others [3] . HDACis have been the most scrutinized class of compounds and includes suberoylanilide hydroxamic acid (SAHA, also known as vorinostat), which is approved by the FDA for the treatment of cutaneous T-cell lymphoma [4] .
The ability of SAHA to activate HIV has been assessed in two separate clinical trials (ClinicalTrials.gov registry numbers NCT01319383 and NCT01365065) with several others currently recruiting (NCT02475915, NCT02336074, and NCT01249443). Analysis of data from the completed trials indicates that SAHA induces the production of cell-associated HIV RNA in the vast majority of HIV-infected individuals but activation of HIV varies from donor to donor, and a concurrent increase in plasma HIV RNA associated with virions is difficult to detect [5] [6] [7] . Encouragingly, two other HDACis, panobinostat and romidepsin, may have greater potency for activating HIV [8, 9] , and are currently being assessed in clinical trials (NCT01933594 and NCT01680094, respectively). However, the off-target effects of these compounds are even less understood than for SAHA. Therefore, the full extent of SAHA's clinical utility in a shock and kill strategy remains to be evaluated. Current clinical trials assess shock compounds in isolation and future studies are required to assess compounds in combinations. Due to SAHA's ability to activate HIV transcription, it is plausible that SAHA will be included in future combination therapies in conjunction with compounds that can relieve the inhibition that is restricting virion production [7] .
HDACis cause hyperacetylation of histones by preventing deacetylation, leading to chromatin unwinding and recruitment of transcriptional machinery [10] . HIV transcription is thought to occur at least partly through this mechanism at sites where HIV is integrated in the host genome, but activation may also involve nonhistone targets, and is not yet fully understood [11] . It has been hypothesized that HDACis alter the expression of host genes that influence HIV activation, but the identities of these host genes are largely unknown [11] . The nonspecific nature of histone acetylation suggests that widespread effects on host gene expression are likely to occur, so it is also important to investigate the potential for off-target side-effects of SAHA in immunocompromised patients. Furthermore, the optimal dosing regimen for SAHA has not yet been determined for HIV patients. The currently recommended oral dose of 400 mg, once daily, results in a peak serum concentration of 1.2 mmol/l [4] . Intravenous dosing results in peak serum concentration of 9.1 mmol/l, and was surprisingly better tolerated than oral dosing in clinical trials for cancer [12] .
Our laboratory previously reported minimal off-target effects on host gene expression for primary CD4 þ T cells treated for 24 h with 0.34 mmol/l SAHA [13] . Only 37 of 1880 significantly modulated genes had expression changes above two-fold. However, SAHA-modulated gene expression has not previously been examined over the entire concentration range relevant to HIV cure strategies. Our goal was to identify SAHA doseresponsive genes that could be used as in-vivo biomarkers of SAHA activity. Primary CD4 þ T cells were treated with 0.34, 1, 3, or 10 mmol/l of SAHA. Genes consistently up or downregulated in a dose-dependent manner were identified. Host cell functions affected by these genes may have implications for the efficacy and safety of therapies for both HIV and cancer.
Methods

Isolation of primary CD4 R T cells
Human peripheral blood was drawn according to institutional review board approved protocols from nine healthy HIV-seronegative donors by venipuncture and collected into sodium heparin containing tubes. Peripheral blood mononuclear cells (PBMCs) were collected from fresh whole blood by centrifugation. Primary CD4 þ T cells were isolated from PBMCs with RosetteSep CD4 þ Isolation Kits according to manufacturer protocol (Stem Cell Technologies). CD4 þ T cells were incubated at 37 8C, 5% CO 2 overnight in RPMI-1640 with 5% human serum AB. CD4 þ T-cell purity and activation were assessed with flow cytometry. All samples included in microarray analysis had more than 95% purity with fewer than 10% activated cells (i.e. <10% expressing HLA-DR).
Suberoylanilide hydroxamic acid treatment of primary CD4 R T cells CD4 þ T cells were aliquoted into six-well plates; 5 million cells per well in 2 ml of media (RPMI-1640 with 5% human serum AB). These cells were treated with 0.34, 1, 3, or 10 mmol/l SAHA (Merck & Co., Inc., Kenilworth, New Jersey, USA) in 0.1% DMSO, or with only 0.1% DMSO, and incubated at 37 8C, 5% CO 2 for 24 h.
Microarray analysis of gene expression
RNA was extracted from treated cells using Qiagen RNeasy kits according to manufacturer protocol. RNA integrity numbers (RINs) were determined with the Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, California, USA). RNA samples for five conditions from six donors were submitted for microarray analysis (N ¼ 30) and had RINs between 7.9 and 9.0 with an average RIN of 8.5. cRNA was generated and hybridized to IlluminaHT-12 v3 BeadChips (48 803 probes). Expression data were extracted with Genome-Studio (Illumina Inc., San Diego, California, USA); genes with undetectable expression were excluded from analysis. The lumi package [14] in bioconductor was used to transform (variance-stabilizing) and normalize (robust spline) raw expression data. Genes significantly modulated across SAHA doses were identified using a likelihood ratio test in the R package Isogene GX [15] . The family-wise error rate was controlled using Bonferroni-adjusted P-values (P < 0.05). A subset of SAHA dose-responsive genes was identified and used in all subsequent analyses; included genes had consistent trends of upregulation or downregulation across each increasing SAHA dose, and greater than two-fold change in expression when comparing the highest dose (10 mmol/l) to DMSO-treated controls. Unless specified, all analyses were corrected for multiple comparisons using the Benjamini-Hochberg method [16] with an FDR-corrected P-value 0.05 considered significant (i.e. q-value 0.05). Gene expression data are available at the Gene Expression Omnibus (http://www.ncbi.nlm.nih. gov/geo/): accession number GSE66994.
Gene ontology, pathway, and protein interaction network analysis Gene ontology terms significantly overrepresented for SAHA dose-responsive genes were identified using the BiNGO plugin for Cytoscape [17] . KEGG and BIOCARTA biological pathways significantly overrepresented for SAHA dose-responsive genes were identified and characterized with DAVID [18, 19] . A direct protein interaction network (PIN) using a database of literature-curated protein-protein and protein-DNA interactions was constructed for SAHA dose-responsive genes using Metacore (Thomson Reuters, San Diego, California, USA).
Real-time quantitative PCR
Microarray expression data was confirmed by RT-qPCR for the top SAHA dose-responsive gene in samples (five SAHA treatments in each of six donors), as described previously [13] . Briefly, RNA was reverse transcribed using qScript cDNA SuperMix (Quanta Biosciences, Inc., Gaithersburg, Maryland, USA). Expression was confirmed for the three most upregulated (CTNNAL1, H1F0, IRGM) and three most downregulated (DPEP2, PHF15, SELL) SAHA dose-responsive genes (Supplemental Table 1 , http://links.lww.com/QAD/A762) with TaqMan assays according to manufacturer protocols (TaqMan Universal Master Mix II, ABI Prism 7900HT; Life Technologies, Carlsbad, California, USA). Expression data were normalized to RPL27; a gene previously determined to be nonresponsive to SAHA [13] . The 2 -DDCt method [20] was used to determine fold change in SAHA treated samples.
Chromatin immunoprecipitation
Three additional donors were recruited for chromatin immunoprecipitation (ChIP) analysis of SAHA-induced histone modifications. CD4 þ T cells were isolated and treated with SAHA as described above. Chromatin was isolated and processed using ChIP-IT High Sensitivity kits (Active Motif, Carlsbad, California, USA) according to the manufacturer's instructions, except as noted. DNA was cross-linked to protein by a 5-min incubation in fresh 1% formaldehyde and sheared to an average size of 500-1500 base pairs by sonication in 0.1% SDS lysis buffer (Covaris M220 Sonicator; 6 min, 6% duty factor, 200 counts/burst, 75 W). DNA complexes were immunoprecipitated with ChIP-grade antibodies directed against total histone H3 (H3), acetylated-H3 Lysine 9 (H3K9a), acetylated-total histone H4 (H4a), methylated-H3K4 (H3K4m), methylated-H3K27 (H3K27m), and RNA polymerase II (Pol II). Following cross-link reversal and DNA purification, RT-qPCR was conducted using primers and probes (Supplemental Table 1 , http://links. lww.com/QAD/A762) designed to span regions where histone modifications are known to occur; these regions were identified using the UCSC Genome Browser histone track (http://genome.ucsc.edu/) [21] . Chromatin concentration was normalized to non-IP input control chromatin, and then histone acetylation or methylation for six SAHA dose-responsive test genes (CTNNAL1, DPEP2, H1F0, IRGM, PHF15, SELL) was normalized to total H3. The 2 -DDCt method was used to calculate enrichment of histone modifications; this value was log 2 transformed for plotting. The significance of SAHAmodulated changes in histone modification was determined with a one-tailed, paired t-test (P 0.05). For each SAHA dose, RNA was isolated from treated donor samples for RT-qPCR validation of SAHA dose-responsiveness in test genes, as described above.
Predicted transcription factor binding site analysis
The DiRE web server (http://dire.dcode.org) was used to identify transcription factor binding sites enriched in SAHA-modulated genes [22] . Predicted key transcription factors were ranked by an 'importance' score reflecting a transcription factor's association with genes that are coexpressed following treatment, as well as its occurrence in candidate regulatory elements. Predicted transcription factors with an importance score 0.1 at least were incorporated into PINs with SAHA-modulated genes, as described above.
Results
Suberoylanilide hydroxamic acid dose-response genes
To examine the effect of SAHA on host function in CD4 þ T-cells, we utilized microarray analysis to identify 3477 genes with a SAHA dose-responsive trend. This set was filtered to retain only genes with a fold change greater or equal to 2, or less than or equal to -2, and a consistent trend in expression across each increasing SAHA dose. This filter identified 1382 genes (Supplemental Table 2 , http://links.lww.com/QAD/A762) whose expression was consistently responsive to dose, of which 657 were upregulated and 725 downregulated. This higher confidence subset was used in all analyses of SAHAmodulated gene expression, and is referred to hereafter as 'dose-responsive genes'.
Our previous study in primary CD4 þ T cells exposed to 0.34 mmol/l SAHA for 24 h identified 1847 differentially expressed genes [13] . Only 29% of these genes were found to be dose-responsive across the concentration range of SAHA used in this study. This suggests that not all differentially expressed genes at this low dose of SAHA are truly dose-responsive, indicating the risks of relying on a single dose to identify gene expression biomarkers for SAHA response.
RT-qPCR analysis of microarray samples ( Fig. 1 ) confirmed dose-responsive changes in expression and consistent trends of up or downregulation in all six test genes across each tested SAHA dose. These genes represent gene expression biomarkers of SAHA, which are relevant over the concentration range examined here (0.34-10 mmol/l).
Suberoylanilide hydroxamic acid doseresponsive genes associated with HIV replication
Literature-based searches identified host dose-responsive genes with prior evidence of involvement in HIV activation or replication. A number of SAHA doseresponsive genes (summarized in Table 1 ) have functions relating to histone methylation, transcription, HIV restriction, HIV protein interaction and cell surface receptors, which on the whole likely enhance HIV activation.
Gene ontology and pathway analysis of suberoylanilide hydroxamic acid dose-responsive genes Gene ontology terms for biological processes related to T-cell activation, apoptosis, and chromatin organization were significantly overrepresented (Supplemental genes primarily retained gene ontology terms related to chromatin organization (Supplemental Figure 2 , http:// links.lww.com/QAD/A762). In contrast, analysis using only downregulated genes identified terms related to T-cell activation and apoptosis (Supplemental Figure 3 , http://links.lww.com/QAD/A762). Pathway mapping of dose-responsive genes identified significant pathways only in downregulated genes (q-value 0.05) [23] ; In downregulated genes, significant KEGG and BIO-CARTA pathways were focused on T-cell receptor signaling, apoptosis, and cytotoxic T-lymphocyte mediated immune response ( Table 2 ). Further analysis of expression patterns for genes associated with the T-cell receptor signaling pathway (KEGG) suggests a possible SAHA-induced net decrease in T-cell activation (Supplemental Figure 4 , http://links.lww.com/QAD/A762). There was no consistent trend in apoptosis-related gene expression, so the net effect of SAHA on apoptosis could not be predicted (data not shown). This is consistent with previous results showing no cytopathic effects from SAHA-induced HIV reactivation [24] .
Suberoylanilide hydroxamic acid-induced histone modification
We conducted ChIP-RT-qPCR assays in primary CD4 þ T cells to determine whether histones were hyperacetylated (H3K9a and H4a) as a consequence of SAHA treatment. Having identified numerous SAHA dose-response expression in CD4 R T cells Reardon et al. 2239 Table 1 ), ChIP-RT-qPCR also examined histone methylation associated with gene activation (H3K4m) and repression (H3K27m). H3K4-methylation was selected because five of 11 HMTs modulated by SAHA are known to methylate this site [25] [26] [27] [28] [29] . The most strongly upregulated HMT, EZH2, methylates H3K27, causing transcriptional repression [30] . Histone modifications were studied in the three most upregulated genes and three most downregulated genes. Expression of these genes was confirmed in ChIP donor samples, demonstrating expression patterns similar to previously tested microarray samples (Fig. 1 ).
SAHA-modulated histone methyltransferases (HMTs,
Histone markers of transcriptional activation (H3K9a, H4a, and H3K4m) were consistently enriched, often attaining significance in the three SAHA-upregulated genes (Fig. 2a) . Unexpectedly, histone acetylation was also detected in two of three SAHA-downregulated genes, DPEP2 and SELL (Fig. 2b) . H3K4-methylation was not significantly different from vehicle in any of the downregulated genes. Trends in pol II enrichment were generally consistent with the known patterns of expression for these genes; however, significance was reached only for IRGM (increased pol II, SAHAupregulated) and PHF15 (decreased pol II, SAHAdownregulated). H3K27-methylation was not correlated with SAHA-modulated gene expression. The enrichment patterns of histone modifications associated with transcriptional activation were consistent with gene upregulation, but did not explain SAHA-induced gene downregulation.
Suberoylanilide hydroxamic acid doseresponsive transcription factor modulation A PIN (Supplemental Figure 5 , http://links.lww.com/ QAD/A762) containing SAHA dose-responsive genes identified key hubs through which SAHA may influence expression of additional genes; as summarized in Table 3 . The most connected hub in the protein network was the transcription factor, c-Myc. Other large hubs were mostly downregulated and corresponded to transcription factors or coactivators (C/EBPbeta, p300, ETS1 and STAT1). were also among the most connected hubs in our previous study summarizing differential expression in primary CD4 þ T cells treated with 0.34 mmol/l SAHA [13] .
We also explored the possibility that SAHA might modulate activity of transcription factors through other mechanisms (e.g. transcription factor acetylation). Candidate transcription factors were identified among SAHA-responsive genes using DiRE [22] , to find enrichment in consensus transcription factor binding sites within regulatory elements of co-expressed genes. Transcription factor analysis identified 13 total candidate transcription factors among SAHA dose-responsive genes: eight among upregulated and five among downregulated genes. The highest confidence predictions are shown in Supplemental Figure 6 , http://links.lww.com/ QAD/A762. SAHA treatment decreased expression of three predicted transcription factors (ETS1, STAT6, and the RUNX1 component of Core Binding Factor) with enrichment for consensus binding sites in downregulated genes; all three were hubs in the PIN of SAHAmodulated genes. Furthermore, when SAHA-nonresponsive, DiRE-predicted transcription factors were analyzed for interactions with SAHA dose-responsive genes, the resulting PIN had SP1, TAL1, and MYOD emerging as major hubs; with curated evidence of acting on 156, 35, and 30 SAHA-modulated proteins, respectively (Table 3 ).
Discussion
This study revealed large numbers of genes modulated by SAHA in a dose-dependent manner in primary CD4 þ T cells. Six of the most dose-responsive genes were validated by RT-qPCR (CTNNALI, DPEP, H1F0, IRGM, PHF15, SELL), suggesting they could be useful in vivo biomarkers for monitoring SAHA activity in current (NCT02475915, NCT02336074 and NCT01249443) and future clinical trials, as well as in trials of other HDACis such as romidepsin and panobinostat (NCT01933594 and NCT01680094). Encouragingly, the SAHA gene expression biomarkers PH15 and H1F0 identified in this study appear to have broad applicability for other compartments and cell types (e.g. whole blood and PBMCs), in other species (e.g. mouse and rhesus macaques), and for other HDACis (e.g. panobinostat) (Drs Richard Barnard and Bonnie Howell, Merck & Co. Inc., personal communication).
Acetylation of histones only partially explains the effects of SAHA on host cell gene expression [31] [32] [33] [34] . ChIP-RT-qPCR based evaluation of histone modifications in the six most SAHA dose-responsive genes (Fig. 2 ) demonstrated that increased histone acetylation was generally observed regardless of gene upregulation or downregulation. The PIN of SAHA-modulated genes revealed several transcription factors that were major hubs (Table 3) . Therefore, by altering expression or activity of SAHA dose-response expression in CD4 R T cells Reardon et al. 2241 Table 3 . Major hubs (>20 edges) in the protein interaction network of suberoylanilide hydroxamic acid (SAHA) dose-responsive genes combined with transcription factors predicted to bind in the promoters of suberoylanilide hydroxamic acid-modulated genes. transcription factors, it is plausible that SAHA influences secondary effects (including downregulation) on scores of other genes.
This study identified several SAHA dose-responsive host genes that may contribute to SAHA's ability to facilitate HIV activation (Table 1) . With respect to enhancing HIV activation, the protein products of IRGM and HSP70 have demonstrated direct interactions with HIV proteins to promote viral replication [35, 36] and were strongly upregulated by SAHA. Furthermore, several HIV restriction factors, APOBEC3G, APOBEC3F, EV12B, and TRIM22 [37] were downregulated in a dosedependent manner by SAHA. Downregulation of MYC, the most connected hub in our PIN, is likely to be an important contributor to HIV activation by SAHA, as we have reported previously [13] . The transcription factor SP1 had predicted binding sites in a large proportion of upregulated genes and was a major hub when combined in a PIN with SAHA-modulated genes. Although no change in SP1 expression was detected, HDACi treatment can acetylate the SP1 protein, enhancing its ability to bind the HIV LTR and promote viral transcription [11] . Thus, SAHA may alter SP1 activity by direct acetylation without changing its expression, contributing to HIV activation. In contrast, with respect to repressing HIV activation, several transcription factors (ETS1, CEBPB, LEF1) shown to bind the HIV LTR and activate HIV transcription [38] [39] [40] were downregulated by SAHA. Furthermore, two cell surface molecules (CCL5/RANTES and ITGAL/CD11a) downregulated by SAHA are thought to enhance cell-to-cell transmission of the activated virus [41] [42] [43] . Finally, a number of histone methyltransferases were modulated by SAHA with half being upregulated and half downregulated ( Table 1) . This represents a heterogenous signal with respect to HIV activation where broad and specific methyltransferase inhibitors have been shown to activate HIV from latency [44, 45] . These observations support recent findings from the gene expression analysis of samples from clinical trials with SAHA suggesting that multiple mechanisms may contribute to HIV activation [7] . Beyond the ability to directly activate HIV through the relaxation of chromatin, SAHA may operate through indirect mechanisms by modulating host genes some of which appear to have positive and others negative roles with respect to HIV activation. For the majority of the genes listed in Table 1 , SAHA-induced changes in expression would likely favor HIVactivation from latency. However, recent evidence suggests that HIV activation from latency may also require removal of an as yet unknown post-transcriptional block [46] ; no obvious candidates for such an activity emerged from our results.
Analysis of functional categories and pathways associated with SAHA-modulated genes revealed categories related to T-cell activation and suggested possible downregulation of T-cell receptor activation. Several studies implicate T-cell activation as an essential component for efficient HIV infection and replication. Possible consequences of SAHA impeding T-cell activation may include decreased HIV transcription and translation, which may diminish eradication of infected cells during ART. This is consistent with a recent study in a primary CD4 þ T-cell latency model showing that SAHA treatment resulted in only a modest increase in HIV protein despite a three-fold increase in HIV transcription [46] . Our data suggest that T-cell receptor activation may require particular scrutiny when evaluating dosing regimens for SAHA, or future analogues with increased bioavailability or potency.
The possible utilization of SAHA to activate latent HIV is still being evaluated in clinical trials, so it is too early to know whether it will have a key role in a shock and kill approach to an HIV cure. In the event that SAHA does not show the desired efficacy on its own, it may still be used as part of a combination therapy with other latency activating compounds. Our results indicated plausible alternative mechanisms of action for SAHA that may help to identify additional therapies or adjuvants that can be used to maximize the effectiveness of a cure strategy. This current study was focused on gene expression in primary resting CD4 þ T cells because these cells are considered the primary reservoir of latent HIV infection in the peripheral blood. Future work will profile the effects of SAHA and other latency reversing agents in PBMCs, as well as other cell subsets and tissues to further elucidate the effects of SAHA.
In summary, the primary outcome of this work was the identification of gene expression biomarkers of SAHA administration (CTNNALI, DPEP, H1F0, IRGM, PHF15, SELL). These results further indicated other possible mechanisms through which SAHA may affect activation of HIV from latency. Our data suggest that SAHA alters host gene expression through the combined action of multiple mechanisms, including histone acetylation, histone methylation, and altered expression and possible acetylation of transcription factors. These results may be used to identify targets for future knockdown or overexpression studies using in-vitro HIV latency models to determine the contribution of host genes to the SAHA-induced activation of HIV. All authors reviewed the manuscript and accepted it for publication. We would like to express our gratitude to the reviewers of this manuscript whose advice resulted in a higher quality publication. Finally, this manuscript is dedicated to the Community Advisory Board of the CARE Collaboratory (Lynda Dee, Jeff Taylor, Alasdair Burton, Tyler Fisher, Andy Kaytes, Damian Kelly, Jeffrey Mazo, David Palm, Tim Rogers, Jeff Sheehy, and Lorren Willenberg) whose partnership in the quest for finding a cure for HIV has been invaluable.
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